MENU
+Compare
CURE
ETF ticker: NYSE ARCA
AS OF
Jan 17, 04:59 PM (EDT)
Price
$96.77
Change
-$1.96 (-1.99%)
Net Assets
177.88M

CURE stock forecast, quote, news & analysis

Category: @Trading
CURE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for CURE with price predictions
Jan 08, 2025

CURE in +2.84% Uptrend, growing for three consecutive days on January 08, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CURE advanced for three days, in of 334 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CURE's RSI Oscillator exited the oversold zone, of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on January 03, 2025. You may want to consider a long position or call options on CURE as a result. In of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CURE just turned positive on December 27, 2024. Looking at past instances where CURE's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CURE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CURE entered a downward trend on December 31, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Unitedhealth Group (NYSE:UNH), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), ABBVIE (NYSE:ABBV), Abbott Laboratories (NYSE:ABT), Pfizer (NYSE:PFE), Amgen (NASDAQ:AMGN), Intuitive Surgical (NASDAQ:ISRG), Elevance Health (NYSE:ELV).

Industry description

The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the Health Care Select Sector Index. The fund invests at least 80% of its net assets in financial instruments, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index includes domestic companies from the healthcare sector, which includes: pharmaceuticals; health care equipment and supplies; health care providers and services; biotechnology; life sciences tools and services; and etc. It is non-diversified.

Market Cap

The average market capitalization across the Direxion Daily Healthcare Bull 3X ETF ETF is 88.77B. The market cap for tickers in the group ranges from 9.7B to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is HSIC at 9.7B.

High and low price notable news

The average weekly price growth across all stocks in the Direxion Daily Healthcare Bull 3X ETF ETF was 1%. For the same ETF, the average monthly price growth was 6%, and the average quarterly price growth was -19%. CVS experienced the highest price growth at 10%, while MRNA experienced the biggest fall at -19%.

Volume

The average weekly volume growth across all stocks in the Direxion Daily Healthcare Bull 3X ETF ETF was 7%. For the same stocks of the ETF, the average monthly volume growth was -10% and the average quarterly volume growth was 36%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 58
Price Growth Rating: 50
SMR Rating: 61
Profit Risk Rating: 57
Seasonality Score: -8 (-100 ... +100)
View a ticker or compare two or three
CURE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Trading

Profile
Fundamentals
Details
Category
Trading--Leveraged Equity
Address
Direxion Shares ETF Trust33 Whitehall Street,10th FloorNew York
Phone
866-476-7523
Web
http://www.direxioninvestments.com/